9-halo-2-prostaglandin derivatives, processes for the preparation
thereof and use thereof as medicinal agents
    131.
    发明授权
    9-halo-2-prostaglandin derivatives, processes for the preparation thereof and use thereof as medicinal agents 失效
    9-卤-2-前列腺素衍生物,其制备方法及其作为药物的用途

    公开(公告)号:US4699920A

    公开(公告)日:1987-10-13

    申请号:US770350

    申请日:1985-09-17

    CPC分类号: C07C405/0041 C07C405/00

    摘要: The invention relates to 9-halo-.DELTA..sup.2 -prostane derivatives of general Formula I ##STR1## wherein Hal is a fluorine or chlorine atom in the .alpha.- or .beta.-position,R.sub.1 is the residue OR.sub.2 with R.sub.2 meaning a hydrogen atom, alkyl, cycloalkyl, aryl or a heterocyclic residue; or the residue NHR.sub.3 wherein R.sub.3 means an acid residue or the residue R.sub.2 andA is a --CH.sub.2 --CH.sub.2 -- or cis-CH.dbd.CH--group,B is a --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH-- or --C.tbd.C--group,W is a free or functionally modified hydroxymethylene or ##STR2## wherein the respective OH-groups can be in the .alpha.- or .beta.-position,D and E jointly mean a direct bond orD is a straight- or branched-chain alkylene group of 1-10 carbon atoms, which can optionally be substituted by fluorine atoms,E is an oxygen or sulfur atom, a direct bond, a --C.tbd.C--bond or a --CR.sub.6 .dbd.CR.sub.7 --group wherein R.sub.6 is a hydrogen atom or an alkyl group and R.sub.7 is a hydrogen atom, an alkyl group or a halogen atom,R.sub.4 is a free or functionally modified hydroxy group,R.sub.5 is a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a cycloalkyl group, an optionally substituted aryl group, or a heterocyclic group,and, if R.sub.2 means a hydrogen atom, the salts thereof with physiologically compatible bases.

    摘要翻译: PCT No.PCT / DE84 / 00280 Sec。 371日期:1985年9月17日 102(e)日期1985年9月17日PCT提交1984年12月21日PCT公布。 出版物WO85 / 02841 日期:1985年7月4日本发明涉及通式Ⅰ(I)的9-卤代-TATA 2-前列腺衍生物,其中Hal是α-或β-位中的氟或氯原子,R1是 残基OR2与R2表示氢原子,烷基,环烷基,芳基或杂环残基; 或残基NHR 3,其中R 3表示酸残基或残基R2和A是-CH 2 -CH 2 - 或顺式-CH = CH-基团,B是-CH 2 -CH 2 - 或反式-CH = CH-或-C 第三个C基团,W是游离的或官能改性的羟基亚甲基或者其中相应的OH基团可以是α-或β-位,D和E共同指直接键或D是直链或支链 可以任选被氟原子取代的1-10个碳原子的链状亚烷基,E是氧或硫原子,直接键,-C 3 C C键或-CR 6 = CR 7 - 基,其中R 6是 氢原子或烷基,R 7为氢原子,烷基或卤素原子,R 4为游离或官能改性的羟基,R 5为氢原子,烷基,卤素取代的烷基, 环烷基,任选取代的芳基或杂环基,如果R 2表示氢原子,则其与生理上相容的碱的盐。

    Pharmaceutically active 9-chloroprostaglandins
    132.
    发明授权
    Pharmaceutically active 9-chloroprostaglandins 失效
    药用活性9-氯前列腺素

    公开(公告)号:US4444788A

    公开(公告)日:1984-04-24

    申请号:US387140

    申请日:1982-06-10

    CPC分类号: C07C405/00 C07C405/0041

    摘要: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.- or .beta.-position,R.sub.1 is OR.sub.2, or NHR.sub.3 wherein R.sub.3 is H or the acyl group ofa C.sub.1-15 hydrocarbon carboxylic or sulfonic acid;A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --,trans--CH.dbd.CH--, or --C.tbd.C--, ##STR2## wherein the OH-group in each case can be in the .alpha.- or .beta.-position, and can be etherified or esterified by tetrahydropyranyl, tetrahydrofuranyl, .alpha.-ethoxyethyl, trimethylsilyl dimethyl, tert-butylsilyl, tribenzylsilyl, acetyl, propionyl, butyryl or benzoyl;D and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.1-10 hydrocarbon, aliphatic group substituted by aryl, a substituted aryl as defined for R.sub.2 above, or halogen; or cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or aromatic heterocyclic, all as defined for R.sub.2 above;or a physiologically acceptable salt thereof with a base when R.sub.1 is OH,have valuable pharmacological properties.

    摘要翻译: 其中9-氯原子可以是α-或β-位,R1是OR2或NHR3,其中R3是H或C1-15烃羧酸或磺酸的酰基; A是-CH 2 -CH 2 - 或顺式-CH = CH-,B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3位C,,其中每种情况下的OH-基团可以是 四氢呋喃基,α-乙氧基乙基,三甲基甲硅烷基二甲基,叔丁基甲硅烷基,三苄基甲硅烷基,乙酰基,丙酰基,丁酰基或苯甲酰基可以醚化或酯化。 D和E一起代表直接键或D是1-10个碳原子的直链或支链亚烷基,任选被氟取代,E是氧或硫或直接键,并且R 4是羟基或羟基醚化或 酯化如上述W所定义; R5是C1-10烃脂族基团; C1-10烃基,被芳基取代的脂族基团,对上述R2定义的取代芳基或卤素; 或环烷基,取代的环烷基,芳基,取代的芳基或芳族杂环,全部如上述R2所定义; 或其生理上可接受的盐,当R1为OH时,具有有价值的药理学性质。

    Process for the production of caracyclin intermediates
    133.
    发明授权
    Process for the production of caracyclin intermediates 失效
    生产青蒿素中间体的方法

    公开(公告)号:US4359581A

    公开(公告)日:1982-11-16

    申请号:US270716

    申请日:1981-06-05

    CPC分类号: C07C405/0083

    摘要: A process for preparing a 3-oxo-7-hydroxy-bicyclo[3,3,0]octan-2-ylcarboxylic acid ester of the formula ##STR1## wherein R.sub.1 is alkyl of 1-6 carbon atoms or phenalkyl of 7-10 carbon atoms andR.sub.2 is hydrogen, alkyl or 1-6 carbon atoms, phenalkyl of 7-10 carbon atoms, tetrahydropyranyl, tetrahydrofuranyl, .alpha.-ethoxyethyl, tri-C.sub.1-4 -alkylsilyl, wherein the alkyl moieties can optionally be substituted by phenyl, or ##STR2## wherein R.sub.3 is alkyl of 1-6 carbon atoms or aryl of 6-12 carbon atoms, comprises oxidizing the corresponding 7-hydroxy-2-oxabicyclo [3,3,0]octan-3-ylideneacetic acid ester of the formula ##STR3## wherein R.sub.1 and R.sub.2 are as defined above, to form the corresponding ketone, reacting the latter with a base which opens the ether oxygen containing ring, and then reducing the resultant product to prepare the 3-oxo-7-hydroxy-bicyclo[3,3,0]octan-2-ylcarboxylic acid ester.

    摘要翻译: 制备下式的“3-氧代-7-羟基 - 双环[3,3,0]辛-2-基羧酸酯的方法,其中R1是1-6个碳原子的烷基或7-10的苯基烷基 碳原子,R 2是氢,烷基或1-6个碳原子,7-10个碳原子的苯基烷基,四氢吡喃基,四氢呋喃基,α-乙氧基乙基,三-C 1-4 - 烷基甲硅烷基,其中烷基部分可以任选被苯基取代, 或者其中R 3为1-6个碳原子的烷基或6-12个碳原子的芳基,包括将相应的7-羟基-2-氧杂双环[3,3,0]辛-3-基亚乙基乙酸酯氧化为 其中R 1和R 2如上定义,以形成相应的酮,使后者与打开醚氧环的碱反应,然后还原所得产物以制备3-氧代-7-羟基 - 双环[3,3,0]辛-2-基羧酸酯。

    Novel 11-oxoprostaglandin derivatives
    134.
    发明授权
    Novel 11-oxoprostaglandin derivatives 失效
    新型11-氧代前列腺素衍生物

    公开(公告)号:US4346228A

    公开(公告)日:1982-08-24

    申请号:US677420

    申请日:1976-04-15

    摘要: 11-Oxoprostaglandin derivatives of the formula ##STR1## wherein R.sub.2 is a hydrogen atom or alkyl of 1-5 carbon atoms,R.sub.3 is alkyl of 1-5 carbon atoms, alkylaryl, cycloalkyl of 5-6 ring carbon atoms and a total of 5-10 carbon atoms; benzodioxol-2-yl, phenyl, naphthyl or phenyl or naphthyl substituted by phenyl, halogen, alkyl of 1-4 carbon atoms, chloromethyl, fluoromethyl, carboxyl or hydroxy;A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, or trans--CH.dbd.CH--;B is --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH--,D and E collectively are a direct bond or D is alkylene of 1-5 carbon atoms and E is an oxygen or sulfur atom; esters thereof; readily cleavable 9,15 and 9,15 ethers thereof; methanesulfonylamides thereof, and physiologically acceptable salts thereof with bases; possess the activity of the corresponding natural prostaglandins with a surprisingly longer duration of effectiveness, greater selectivity, and better effects, and can be produced, e.g., by oxidation of the corresponding 9-hydroxy prostaglandins.

    摘要翻译: 其中R2是氢原子或1-5个碳原子的烷基,R3是1-5个碳原子的烷基,烷基芳基,5-6个环碳原子的环烷基和总共5个碳原子的11-前列酰乳糖衍生物 -10个碳原子; 苯基二氧杂环戊烯-2-基,苯基,萘基或被苯基,卤素,1-4个碳原子的烷基取代的苯基或萘基,氯甲基,氟甲基,羧基或羟基; A是-CH 2 -CH 2 - ,顺式-CH = CH-或反式-CH = CH-; B是-CH 2 -CH 2 - 或反式-CH = CH-,D和E共同是直接键或D是1-5个碳原子的亚烷基,E是氧或硫原子; 其酯; 易于切割的9,15和9,15醚; 甲磺酰胺及其与碱的生理学上可接受的盐; 具有相当的天然前列腺素的活性,具有惊人的更长的有效期,更高的选择性和更好的效果,并且可以例如通过相应的9-羟基前列腺素的氧化来产生。